Global Preventive Asthma Drugs Market Overview
Asthma is a common long-term inflammatory disease characterized by variable and recurring symptoms, reversible airflow obstruction, and bronchospasm. Preventive drugs for asthma play a crucial role in managing the diseases and help pacify the risk of asthma attacks. Asthma attacks are preventable in adults but there is still a rising prevalence of asthma, which is closely linked to severity and mortality of the disease. In particular, this is evident in developed nations.
Global Preventive Asthma Drugs Market Drivers & Restraints
Prominent driver of the target market is the high prevalence of the disease owing to rising urbanization and pollution. The need for preventive classes of drugs to keep asthma triggers for patients in check is also boosting growth of the target market. The major restraining factor for the target market is unknown etiology for this condition. Lack of manufacturing facilities, coupled with and high dependence on imports are other key factors hampering growth of the global preventive asthma drugs market in developing economies. Major pharmaceutical companies are investing in their R&D departments for better preventive combination therapies to prevent the disease, which is a key trend in the target market.
Global Preventive Asthma Drugs Market Segmentations & Regional Insights
The target market is segmented by type of asthma, asthma trigger type, drug class, therapy, route of administration, and region.
The types of asthma are allergic and non-allergic. The asthma trigger types are child-onset asthma, adult-onset asthma, exercise-induced asthma, cough-induced asthma, occupational asthma, nocturnal asthma, and steroid-resistant asthma (severe asthma). On the basis of drug class, the target market is divided into bronchodilators (beta agonists, anti-cholinergic, xanthines), leukotriene antagonists, mast cell stabilizers, corticosteroids, and monoclonal antibody. Based upon therapy the global market is segmented into reliever treatment and maintenance treatment. On the basis of routes of drug administration the global market can be categorized as oral, inhaled, intravenous, and subcutaneous.
Global preventive asthma market has been segmented on the basis of region into North America, Asia Pacific, Europe, Latin America, Middle East, and Africa. North America dominates the target market, followed by Europe. Asia Pacific market is expected to witness significant growth during the forecast period owing to increase in incidence of asthma, heightened awareness, and adoption of modern lifestyles.
Global Preventive Asthma Drugs Market Competitive Landscape & Key Players
Key players operating in the global preventive asthma market include GlaxoSmithKline PLC, AstraZeneca PLC, Merck & Company, Inc., Novartis International AG, Boehringer Ingelheim, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals, Inc.
FAQs
The target market is segmented by type of asthma, asthma trigger type, drug class, therapy, route of administration, and region.
Prominent driver of the target market is the high prevalence of the disease owing to rising urbanization and pollution. The need for preventive classes of drugs to keep asthma triggers for patients in check is also boosting growth of the target market.
Asia Pacific market is expected to witness significant growth during the forecast period owing to increase in incidence of asthma, heightened awareness, and adoption of modern lifestyles.
Key players operating in the global preventive asthma market include GlaxoSmithKline PLC, AstraZeneca PLC, Merck & Company, Inc., Novartis International AG, Boehringer Ingelheim, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals, Inc.